Anti-Angiogenesis Strategies in Cancer Therapies
Autor Shaker Mousa, Paul Davisen Limba Engleză Paperback – 30 noi 2016
Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.
- Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents
- Reviews FDA-approved anti-angiogenesis agents
- Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents
- Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
Preț: 420.11 lei
Preț vechi: 658.46 lei
-36% Nou
Puncte Express: 630
Preț estimativ în valută:
80.40€ • 84.82$ • 67.00£
80.40€ • 84.82$ • 67.00£
Carte tipărită la comandă
Livrare economică 26 decembrie 24 - 09 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128025765
ISBN-10: 012802576X
Pagini: 210
Dimensiuni: 152 x 229 x 13 mm
Greutate: 0.32 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 012802576X
Pagini: 210
Dimensiuni: 152 x 229 x 13 mm
Greutate: 0.32 kg
Editura: ELSEVIER SCIENCE
Public țintă
Pharmaceutical scientists and researchers in pharmaceutical and biotechnology companies, oncologists, hematologists, graduate and post-graduate students in these areas and academic facultyCuprins
1. Role of Angiogenesis and lymphogenesis in Cancer (tumor growth, Invasion, metastasis2. Role of Angiogenesis and anti-angiogenesis in hematological malignancies (acute / chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms)3. The interface between Thrombosis-Inflammation and Angiogenesis4. Micro RNA and Angiogenesis modulation5. Preclinical discovery and development of different Pharmacological anti-angiogenesis agents6. Differences among different anti-angiogenesis strategies (Mechanisms of actions)7. Naturally Occurring Anti-angiogenesis8. Clinical trials with anti-angiogenesis agents: Approved agents9. Angiogenesis Biomarkers and Impact on personalized management10. Efficacy of Anti-VEGF therapy in cancer11. Nanotechnology in enhancing the utility of anti-angiogenesis agents – Combinations with other anti-cancer agents12. Multi-targeted anti-angiogenesis therapy in cancer13. Combination of anti-angiogenesis and chemotherapeutics14. Nanotechnology in enhancing the utility of anti-angiogenesis agents – Combinations with other anti-cancer agents15. Nano-targeted anti-angiogenesis agents in cancer detection16. Future Directions
Recenzii
"...a comprehensive overview of all aspects of angiogenesis. The assessment of FDA-approved antiangiogenesis agents in cancer therapy and new applications of nanotechnology in antiangiogenesis interventions are very valuable to the field. Score: 98 - 5 Stars!" --Doody's